Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic Amiodarone in canine atria

Circulation: Arrhythmia and Electrophysiology

Volumn 3, Issue 1, 2010, Pages 88-95

  Sicouri, Serge ^a   Burashnikov, Alexander ^a   Belardinelli, Luiz ^b   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Electrophysiology; Pharmacology; Sodium channel blocker

Indexed keywords

ACETYLCHOLINE; AMIODARONE; RANOLAZINE; SODIUM CHANNEL; ACETANILIDE DERIVATIVE; ANTIARRHYTHMIC AGENT; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIASTOLE; DRUG POTENTIATION; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART EXCITATION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART PACING; HEART REPOLARIZATION; HEART RIGHT ATRIUM; NONHUMAN; PRIORITY JOURNAL; PULMONARY VEIN; SODIUM CURRENT; TREATMENT DURATION; ANIMAL; CELL MEMBRANE POTENTIAL; DOG; DRUG EFFECT; HEART FUNCTION TEST; IN VITRO STUDY; REFRACTORY PERIOD;

ACETANILIDES; AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOGS; DRUG SYNERGISM; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; ENZYME INHIBITORS; MEMBRANE POTENTIALS; PIPERAZINES; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; SODIUM CHANNEL BLOCKERS;

EID: 77649299995     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.109.886275     Document Type: Article

References (42)

1. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas GP. Electrophysiologic effects of ranolazine: a novel anti-anginal agent with antiarrhythmic properties. Circulation. 2004; 110: 904-910. (Pubitemid 39136212)
2. Antzelevitch C, Belardinelli L, Wu L, Fraser H, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Goodrow RJ, Scornik FS, Peréz GJ Electrophysiologic properties and antiarrhythmic actions of a novel anti-anginal agent. J Cardiovasc Pharmacol Therapeut. 2004; 9 (Suppl 1) : S65-S83. (Pubitemid 39334836)
3. Antzelevitch C. Ranolazine: a new antiarrhythmic agent for patients with non-ST-segment elevation acute coronary syndromes? Nat Clin Pract Cardiovasc Med. 2008; 5: 248-249.
4. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007; 116: 1449-1457.
5. Sicouri S, Timothy KW, Zygmunt AC, Glass A, Goodrow RJ, Belardinelli L, Antzelevitch C. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm. 2007; 4: 638-647.
6. Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm. 2008; 5: 1019-1026.
7. Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przbylski J, Levi RJ, Lazzari JO, Elizari MV. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976; 38: 934-944.
8. Singh BN. Amiodarone: a multifaceted antiarrhythmic drug. Curr Cardiol Rep. 2006; 8: 349-355.
9. Burashnikov A, Di Diego JM, Sicouri S, Ferreiro M, Carlsson L, Antzelevitch C. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm. 2008; 5: 1735-1742.
10. Kur block. Am J Physiol. 2004; 286: H2393-H2400.
11. Burashnikov A, Antzelevitch C. Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation. 2003; 107: 2355-2360.
12. Sicouri S, Belardinelli L, Carlsson L, Antzelevitch C. Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol. 2009; 20: 803-810.
13. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol. 1999; 84: 20R-28R.
14. + current. Circulation. 2001; 103: 1317-1324.
15. Sosunov EA, Anyukhovsky EP, Rosen MR. Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts. J Pharmacol Exp Ther. 1996; 278: 906-912.
16. Maruyama T, Richardson LC, Sun W, McCarthy JJ, Gettes LS. Acute effects of amiodarone on membrane properties, refractoriness, and conduction in guinea pig papillary muscles. Heart Vessels. 1995; 10: 78-86.
17. Kirchhof P, Degen H, Franz MR, Eckardt L, Fabritz L, Milberg P, Laer S, Neumann J, Breithardt G, Haverkamp W. Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation. J Pharmacol Exp Ther. 2003; 305: 257-263.
18. Kim YH, Lim HE, Kim SH, Pak HN, Ahn JC, Song WH, Kim YH. Brugada-like ST-segment abnormalities associated with myocardial involvement of hematologic diseases. Pacing Clin Electrophysiol. 2008; 31: 761-764.
19. Sicouri S, Moro S, Litovsky SH, Elizari MV, Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol. 1997; 8: 1269-1279.
20. Burashnikov A, Antzelevitch C. Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol. 2008; 52: 121-128.
21. Levine JH, Moore EN, Kadish AH, Weisman HF, Balke CW, Hanich RF, Spear JF. Mechanisms of depressed conduction from long-term amiodarone therapy in canine myocardium. Circulation. 1988; 78: 684-691.
22. Nanas JN, Mason JW. Pharmacokinetics and regional electrophysiological effects of intracoronary amiodarone administration. Circulation. 1995; 91: 451-461.
23. Morady F, Dicarlo LA, Krol RB, Baerman JM, De Buitleir M. Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol. 1986; 7: 148-157. (Pubitemid 16132469)
24. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. 2006; 17: S161-S177.
25. Whalley DW, Wendt DJ, Grant AO. Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. Pacing Clin Electrophysiol. 1995; 18: 1686-1704.
26. v1.7 voltage-gated Na+ channel isoforms by ranolazine. Mol Pharmacol. 2008; 73: 940-948.
27. Golod DA, Kumar R, Joyner RW. Determinants of action potential initiation in isolated rabbit atrial and ventricular myocytes. Am J Physiol. 1998; 274: H1902-H1913.
28. Haissaguerre M, Jais P, Shah DC, Garrigue S, Takahashi A, Lavergne T, Hocini M, Peng JT, Roudaut R, Clementy J. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation. 2000; 101: 1409-1417.
29. Nattel S, Allessie MA, Haissaguerre M. Spotlight on atrial fibrillation-the 'complete arrhythmia.' Cardiovasc Res. 2002; 54: 197-203.
30. Nattel S. Combined parasympathetic-sympathetic nerve discharge and pulmonary vein afterdepolarizations: a new unifying concept with basic and clinical relevance. Heart Rhythm. 2005; 2: 632-633.
31. Pappone C, Santinelli V, Manguso F, Vicedomini G, Gugliotta F, Augello G, Mazzone P, Tortoriello V, Landoni G, Zangrillo A, Lang C, Tomita T, Mesas C, Mastella E, Alfieri O. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004; 109: 327-334.
32. van Opstal JM, Schoenmakers M, Verduyn SC, De Groot SH, Leunissen JD, Der Hulst FF, Molenschot MM, Wellens HJ, Vos MA. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 2001; 104: 2722-2727.
33. Holt DW, Tucker GT, Jackson PR, McKenna WJ. Amiodarone pharmacokinetics. Br J Clin Pract Suppl. 1986; 44: 109-114.
34. CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989; 321: 406-412.
35. Antzelevitch C, Shimizu W, Yan GX, Sicouri S, Weissenburger J, Nesterenko VV, Burashnikov A, Di Diego JM, Saffitz J, Thomas GP. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol. 1999; 10: 1124-1152.
36. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med. 2007; 356: 935-941.
37. Goldschlager N, Epstein AE, Naccarelli GV, Olshansky B, Singh B, Collard HR, Murphy E. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007; 4: 1250-1259.
38. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation. 2003; 107: 1440-1446.
39. Maury P, Zimmermann M. Effect of chronic amiodarone therapy on excitable gap during typical human atrial flutter. J Cardiovasc Electrophysiol. 2004; 15: 1416-1423.
40. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, Braunwald E. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007; 116: 1647-1652.
41. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Metayer P, Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998; 339: 659-666.
42. Chen YJ, Chen SA. Electrophysiology of pulmonary veins. J Cardiovasc Electrophysiol. 2006; 17: 220-224.